These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24516169)
21. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies. Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503 [TBL] [Abstract][Full Text] [Related]
22. Measurement of Intracellular Sterol Transport in Yeast. Chauhan N; Jentsch JA; Menon AK Methods Mol Biol; 2019; 1949():115-136. PubMed ID: 30790253 [TBL] [Abstract][Full Text] [Related]
23. Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. Soccio RE; Adams RM; Maxwell KN; Breslow JL J Biol Chem; 2005 May; 280(19):19410-8. PubMed ID: 15760897 [TBL] [Abstract][Full Text] [Related]
24. Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity. Usenovic M; Knight AL; Ray A; Wong V; Brown KR; Caldwell GA; Caldwell KA; Stagljar I; Krainc D Hum Mol Genet; 2012 Sep; 21(17):3785-94. PubMed ID: 22645275 [TBL] [Abstract][Full Text] [Related]
26. Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. Badiola N; de Oliveira RM; Herrera F; Guardia-Laguarta C; Gonçalves SA; Pera M; Suárez-Calvet M; Clarimon J; Outeiro TF; Lleó A PLoS One; 2011; 6(10):e26609. PubMed ID: 22039514 [TBL] [Abstract][Full Text] [Related]
27. Transport of newly synthesized sterol to the sterol-enriched plasma membrane occurs via nonvesicular equilibration. Baumann NA; Sullivan DP; Ohvo-Rekilä H; Simonot C; Pottekat A; Klaassen Z; Beh CT; Menon AK Biochemistry; 2005 Apr; 44(15):5816-26. PubMed ID: 15823040 [TBL] [Abstract][Full Text] [Related]
28. Non-vesicular sterol transport in cells. Prinz WA Prog Lipid Res; 2007 Nov; 46(6):297-314. PubMed ID: 17709145 [TBL] [Abstract][Full Text] [Related]
29. Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. Bar-On P; Rockenstein E; Adame A; Ho G; Hashimoto M; Masliah E J Neurochem; 2006 Aug; 98(4):1032-45. PubMed ID: 16895578 [TBL] [Abstract][Full Text] [Related]
30. Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Beyer K; Domingo-Sàbat M; Humbert J; Carrato C; Ferrer I; Ariza A Neurogenetics; 2008 Jul; 9(3):163-72. PubMed ID: 18335262 [TBL] [Abstract][Full Text] [Related]
31. α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate. Schechter M; Atias M; Abd Elhadi S; Davidi D; Gitler D; Sharon R J Biol Chem; 2020 Dec; 295(52):18076-18090. PubMed ID: 33087443 [TBL] [Abstract][Full Text] [Related]
32. α-Synuclein Shows High Affinity Interaction with Voltage-dependent Anion Channel, Suggesting Mechanisms of Mitochondrial Regulation and Toxicity in Parkinson Disease. Rostovtseva TK; Gurnev PA; Protchenko O; Hoogerheide DP; Yap TL; Philpott CC; Lee JC; Bezrukov SM J Biol Chem; 2015 Jul; 290(30):18467-77. PubMed ID: 26055708 [TBL] [Abstract][Full Text] [Related]
34. Osh proteins regulate membrane sterol organization but are not required for sterol movement between the ER and PM. Georgiev AG; Sullivan DP; Kersting MC; Dittman JS; Beh CT; Menon AK Traffic; 2011 Oct; 12(10):1341-55. PubMed ID: 21689253 [TBL] [Abstract][Full Text] [Related]
35. alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. Sharma N; Brandis KA; Herrera SK; Johnson BE; Vaidya T; Shrestha R; Debburman SK J Mol Neurosci; 2006; 28(2):161-78. PubMed ID: 16679556 [TBL] [Abstract][Full Text] [Related]
36. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers. Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040 [TBL] [Abstract][Full Text] [Related]
37. Levels of α- and β-synuclein regulate cellular susceptibility to toxicity from α-synuclein oligomers. Angelova DM; Jones HBL; Brown DR FASEB J; 2018 Feb; 32(2):995-1006. PubMed ID: 29054856 [TBL] [Abstract][Full Text] [Related]
38. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. Benskey MJ; Perez RG; Manfredsson FP J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372 [TBL] [Abstract][Full Text] [Related]
39. A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo. Prabhudesai S; Sinha S; Attar A; Kotagiri A; Fitzmaurice AG; Lakshmanan R; Ivanova MI; Loo JA; Klärner FG; Schrader T; Stahl M; Bitan G; Bronstein JM Neurotherapeutics; 2012 Apr; 9(2):464-76. PubMed ID: 22373667 [TBL] [Abstract][Full Text] [Related]
40. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]